Nivolumab-induced polymyalgia rheumatica in a patient with lung adenocarcinoma.

Published on Apr 24, 2021in The American Journal of the Medical Sciences1.911
· DOI :10.1016/J.AMJMS.2021.04.010
Toshiyuki Kita15
Estimated H-index: 15
Tomoyuki Araya7
Estimated H-index: 7
+ 3 AuthorsKazuo Kasahara28
Estimated H-index: 28
(Kanazawa University)
Abstract A 79-year-old woman was diagnosed with stage IV (cT1aN1M1, OSS) lung adenocarcinoma with bone metastasis of the right femur. She received nivolumab as a third-line treatment. She developed pain in the right shoulder, left wrist, right knee, and waist as well as a low-grade fever and morning stiffness, after five courses of nivolumab. After closer examination, she was diagnosed with polymyalgia rheumatica (PMR) precipitated by an immune-related adverse event. Nivolumab was discontinued, and oral prednisolone was started. Her arthralgia improved. Caution should be exercised regarding the development of PMR when polyarthralgia occurs during nivolumab treatment in patients with lung cancer.
📖 Papers frequently viewed together
5 Citations
17 Citations
#1Cassandra Calabrese (Cleveland Clinic)H-Index: 13
#2Laura C. Cappelli (Johns Hopkins University)H-Index: 17
Last. Leonard H. Calabrese (Cleveland Clinic)H-Index: 72
view all 6 authors...
Objective To assess whether the polymyalgia rheumatica (PMR)-like syndrome reported as an immune related adverse event (irAE) from checkpoint inhibitor therapy is consistent with the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) provisional criteria for PMR. Methods The cases were derived from two sources. Group 1 represents reported cases from three contributing centres. Group 2 was derived from a systematic review of the literature searching for all cas...
23 CitationsSource
#1Marie KostineH-Index: 14
#2L. RouxelH-Index: 1
Last. Thierry SchaeverbekeH-Index: 56
view all 20 authors...
Objectives To evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation with tumour response. Methods This was a single-centre prospective observational study including all cancer patients receiving ICIs. The occurrence of irAEs and tumour response was assessed on a regular basis. Patients who experienced musculoskeletal symptoms were referred to the department of rheumatology for clin...
125 CitationsSource
#1Koichi Sato (Wakayama Medical University)H-Index: 4
#2Hiroaki Akamatsu (Wakayama Medical University)H-Index: 20
Last. Nobuyuki Yamamoto (Wakayama Medical University)H-Index: 41
view all 12 authors...
Abstract Objectives Patients treated with nivolumab often experience its unique adverse events, called immune-related adverse events (irAEs). Regarding the mechanisms of immune-checkpoint inhibitors (ICIs), the occurrence of irAEs may also reflect antitumor responses. Here, we report the clinical correlation between irAEs and efficacy in NSCLC patients treated with nivolumab. Materials and methods Between December 2015 and February 2017, 38 advanced NSCLC patients were treated in our institution...
157 CitationsSource
#1Wilson Kuswanto (Harvard University)H-Index: 6
#2Lindsey A. MacFarlane (Harvard University)H-Index: 14
Last. Bonnie L. Bermas (Harvard University)H-Index: 26
view all 6 authors...
Abstract Objective Immune checkpoint inhibitors are effective cancer therapies that have been associated with immune-related adverse events (irAEs). Recent reports of irAEs describe symptoms resembling classic rheumatologic syndromes, most notably associated with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor blockade. Though cases have been described, there are fewer reports of rheumatologic disease associated with programmed cell death protein-1 (PD-1) inhibitors. Here, we desc...
28 CitationsSource
#1R. BelkhirH-Index: 13
#1Rakiba BelkhirH-Index: 7
Last. Xavier Mariette (University of Paris-Sud)H-Index: 117
view all 15 authors...
Objectives Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 (PD-1) have demonstrated improved survival for multiple cancers. However, these new drug classes have led to increased immune-related adverse events (IrAE). Rheumatic IrAEs have not been well described in clinical trials. We report here cases of rheumatoid arthritis (RA) and polymyalgia rheumatica (PMR) occurring after ICI treatment. Methods This was a retrospe...
119 CitationsSource
#1Koji Haratani (Kindai University)H-Index: 13
#2Hidetoshi Hayashi (Kindai University)H-Index: 29
Last. Kazuhiko Nakagawa (Kindai University)H-Index: 97
view all 11 authors...
Importance Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed cell death protein 1) inhibitors in patients with melanoma, but whether such an association exists for non–small-cell lung cancer (NSCLC) has remained unknown. Objective To evaluate the relation of irAEs to nivolumab efficacy in NSCLC. Design, Setting, and Participants In this study based on landmark and multivariable analyses, a total of 134 patients with advanced or recurrent NSCLC who w...
358 CitationsSource
#1Kiyotaka Nakamagoe (University of Tsukuba)H-Index: 10
#2Tetuya Moriyama (University of Tsukuba)H-Index: 1
Last. Akira Tamaoka (University of Tsukuba)H-Index: 36
view all 8 authors...
10 CitationsSource
#1Marjorie BernierH-Index: 1
#2Cyril GuillauméH-Index: 1
Last. Marion SassierH-Index: 10
view all 11 authors...
The anti-programmed cell-death-1 antibody, nivolumab, has been recently approved for the treatment of advanced non–small cell lung cancer. Although, today, immune-related adverse effects such as dermatologic, digestive, hepatic, and endocrine toxicities are well-known with immune checkpoint inhibito
12 CitationsSource
#1Cassandra Calabrese (Cleveland Clinic)H-Index: 13
#2Elizabeth Kirchner (Cleveland Clinic)H-Index: 8
Last. Leonard H. Calabrese (Cleveland Clinic)H-Index: 72
view all 5 authors...
Immunotherapy of cancer with checkpoint inhibitors has been associated with a spectrum of autoimmune and systemic inflammatory reactions known as immune-related adverse events (irAEs). Rheumatic irAEs are infrequently reported and extensively described. Here, we report our experience over an 18-month period with 15 patients evaluated in the rheumatology department for rheumatic irAEs. We identified 13 patients without pre-existing autoimmune disease (AID) who subsequently developed rheumatic irA...
108 CitationsSource
#1Bethsabée Garel (Paris V: Paris Descartes University)H-Index: 1
#2Nora Kramkimel (Paris V: Paris Descartes University)H-Index: 15
Last. Nicolas Dupin (Paris V: Paris Descartes University)H-Index: 61
view all 5 authors...
Joint Bone Spine - In Press.Proof corrected by the author Available online since mardi 26 avril 2016
19 CitationsSource
Cited By0